Mark E. Gerich

2.5k total citations · 1 hit paper
38 papers, 1.8k citations indexed

About

Mark E. Gerich is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Mark E. Gerich has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 15 papers in Epidemiology and 11 papers in Immunology. Recurrent topics in Mark E. Gerich's work include Inflammatory Bowel Disease (19 papers), Microscopic Colitis (14 papers) and Gut microbiota and health (5 papers). Mark E. Gerich is often cited by papers focused on Inflammatory Bowel Disease (19 papers), Microscopic Colitis (14 papers) and Gut microbiota and health (5 papers). Mark E. Gerich collaborates with scholars based in United States, Ireland and Australia. Mark E. Gerich's co-authors include Sean P. Colgan, Glenn T. Furuta, Daniel J. Kao, Jordi M. Lanis, Erica E. Alexeev, Jörn Karhausen, Simon Keely, Kayla D. Battista, Douglas J. Kominsky and Caleb Kelly and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Mark E. Gerich

36 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor

2018 391 citations Erica E. Alexeev, Jordi M. Lanis et al. American Journal Of Pathology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark E. Gerich United States	18	945	390	383	317	220	38	1.8k
Leiqi Xu China	14	957 1.0×	284 0.7×	162 0.4×	122 0.4×	171 0.8×	22	1.5k
Samuel T. Keating Australia	24	999 1.1×	925 2.4×	326 0.9×	152 0.5×	218 1.0×	39	2.1k
Ravi N. Padia United States	11	1.9k 2.0×	341 0.9×	241 0.6×	275 0.9×	156 0.7×	14	2.5k
Ashish Gurav United States	5	1.6k 1.7×	317 0.8×	253 0.7×	133 0.4×	192 0.9×	8	2.3k
Fausto Sánchez‐Muñoz Mexico	26	779 0.8×	435 1.1×	337 0.9×	237 0.7×	470 2.1×	117	2.3k
Le Liu China	18	883 0.9×	205 0.5×	288 0.8×	97 0.3×	211 1.0×	52	1.6k
Eunha Kim South Korea	18	1.0k 1.1×	328 0.8×	247 0.6×	82 0.3×	356 1.6×	37	2.0k
Sara Omenetti United States	12	870 0.9×	909 2.3×	230 0.6×	93 0.3×	168 0.8×	16	2.1k
Anette Christ Germany	12	1.1k 1.2×	875 2.2×	197 0.5×	102 0.3×	324 1.5×	19	2.2k

Countries citing papers authored by Mark E. Gerich

Since Specialization

Citations

This map shows the geographic impact of Mark E. Gerich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Gerich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Gerich more than expected).

Fields of papers citing papers by Mark E. Gerich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Gerich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Gerich. The network helps show where Mark E. Gerich may publish in the future.

Co-authorship network of co-authors of Mark E. Gerich

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Gerich. A scholar is included among the top collaborators of Mark E. Gerich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Gerich. Mark E. Gerich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cartwright, Ian M., Liheng Zhou, Calen A. Steiner, et al.. (2024). Chlorination of epithelial tight junction proteins by neutrophil myeloperoxidase promotes barrier dysfunction and mucosal inflammation. JCI Insight. 9(14). 10 indexed citations

Cohen, Benjamin L., Phillip Fleshner, Sunanda V. Kane, et al.. (2022). Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 163(1). 204–221. 42 indexed citations

Constant, Brad D., Edwin F. de Zoeten, Marisa G. Stahl, et al.. (2022). Delays Related to Prior Authorization in Inflammatory Bowel Disease. PEDIATRICS. 149(3). 39 indexed citations

Lefferts, Adam R., Mark E. Gerich, Blair Fennimore, et al.. (2021). Circulating mature granzyme B+ T cells distinguish Crohn’s disease-associated axial spondyloarthritis from axial spondyloarthritis and Crohn’s disease. Arthritis Research & Therapy. 23(1). 147–147. 11 indexed citations

Zoeten, Edwin F. de, Kayla D. Battista, Mark A. Lovell, et al.. (2020). <p>Markers of Hypoxia Correlate with Histologic and Endoscopic Severity of Colitis in Inflammatory Bowel Disease</p>. PubMed. Volume 8. 1–12. 9 indexed citations

Hall, Caroline, J. Scott Lee, Emily Murphy, et al.. (2020). Creatine Transporter, Reduced in Colon Tissues From Patients With Inflammatory Bowel Diseases, Regulates Energy Balance in Intestinal Epithelial Cells, Epithelial Integrity, and Barrier Function. Gastroenterology. 159(3). 984–998.e1. 68 indexed citations

Scott, Frank I., Mark E. Gerich, Blair Fennimore, et al.. (2020). Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease. Clinical Gastroenterology and Hepatology. 19(10). 2082–2092.e10. 5 indexed citations

O’Connell, Lauren, Colm B. Collins, Eóin N. McNamee, et al.. (2020). Muc5ac Expression Protects the Colonic Barrier in Experimental Colitis. Inflammatory Bowel Diseases. 26(9). 1353–1367. 31 indexed citations

Scott, Frank I., Michelle Luo, Yash Shah, et al.. (2019). Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. Journal of Crohn s and Colitis. 14(5). 575–587. 6 indexed citations

10.

Alexeev, Erica E., Jordi M. Lanis, Daniel J. Kao, et al.. (2018). Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor. American Journal Of Pathology. 188(5). 1183–1194. 391 indexed citations breakdown →

11.

Lawson, Peter J., Hunter B. Moore, Ernest E. Moore, et al.. (2018). Microfluidics contrasted to thrombelastography: perplexities in defining hypercoagulability. Journal of Surgical Research. 231. 54–61. 2 indexed citations

12.

Neudecker, Viola, Moritz Haneklaus, Owen Jensen, et al.. (2017). Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. The Journal of Experimental Medicine. 214(6). 1737–1752. 305 indexed citations

13.

Kaplan, Jeffrey, et al.. (2017). First Reported Case of Pembrolizumab-Induced Immune Mediated Hemorrhagic Gastritis. Gastroenterology. 152(5). S891–S891. 7 indexed citations

14.

Lanis, Jordi M., Erica E. Alexeev, Valerie F. Curtis, et al.. (2017). Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia. Mucosal Immunology. 10(5). 1133–1144. 152 indexed citations

15.

Chapman, Brandon C., Hunter B. Moore, Douglas M. Overbey, et al.. (2016). Fecal microbiota transplant in patients with Clostridium difficile infection. The Journal of Trauma: Injury, Infection, and Critical Care. 81(4). 756–764. 43 indexed citations

16.

Gerich, Mark E., et al.. (2016). High Hope for Medical Marijuana in Digestive Disorders. The American Journal of Gastroenterology. 111(2). 159–160. 1 indexed citations

17.

Gerich, Mark E., et al.. (2014). Long‐term outcomes of thalidomide in refractory Crohn's disease. Alimentary Pharmacology & Therapeutics. 41(5). 429–437. 19 indexed citations

18.

Gerich, Mark E., et al.. (2013). Tacrolimus Salvage in Anti–Tumor Necrosis Factor Antibody Treatment-Refractory Crohn’s Disease. Inflammatory Bowel Diseases. 19(6). 1107–1111. 10 indexed citations

19.

Gerich, Mark E., et al.. (2010). A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. Journal of Crohn s and Colitis. 4(5). 546–552. 13 indexed citations

20.

Gerich, Mark E., et al.. (2007). Treatment of Inflammatory Bowel Disease with 6-Thioguanine (6-TG): Retrospective Case Series from a Tertiary Care Center. The American Journal of Gastroenterology. 102. S490–S490. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact